Repligen (NASDAQ:RGEN) Shares Gap Up to $157.48

Shares of Repligen Co. (NASDAQ:RGEN - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $157.48, but opened at $166.49. Repligen shares last traded at $171.99, with a volume of 139,951 shares trading hands.

Analyst Upgrades and Downgrades

Several research firms have recently commented on RGEN. KeyCorp upped their target price on Repligen from $210.00 to $220.00 and gave the company an "overweight" rating in a research report on Thursday, February 15th. Stifel Nicolaus upped their target price on Repligen from $165.00 to $207.00 and gave the company a "buy" rating in a report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, Repligen has a consensus rating of "Moderate Buy" and a consensus price target of $196.70.

Repligen Trading Up 8.8 %

The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. The firm has a 50 day moving average price of $187.16 and a 200 day moving average price of $173.44. The stock has a market capitalization of $9.56 billion, a PE ratio of 239.16, a P/E/G ratio of 5.15 and a beta of 1.02.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting analysts' consensus estimates of $0.33. The company had revenue of $155.74 million for the quarter, compared to analysts' expectations of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. Repligen's revenue was down 16.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.68 EPS. Equities analysts expect that Repligen Co. will post 1.46 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Ralf Kuriyel sold 3,517 shares of the business's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, VP Ralf Kuriyel sold 3,517 shares of the business's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now owns 185,249 shares in the company, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock worth $5,039,532 over the last 90 days. Corporate insiders own 1.20% of the company's stock.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently bought and sold shares of RGEN. DekaBank Deutsche Girozentrale increased its position in Repligen by 1.5% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company's stock valued at $1,663,000 after buying an additional 159 shares in the last quarter. International Assets Investment Management LLC boosted its position in Repligen by 18,449.1% in the fourth quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company's stock worth $10,539,000 after purchasing an additional 58,299 shares during the last quarter. American Century Companies Inc. raised its position in Repligen by 97.5% in the third quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company's stock worth $34,648,000 after acquiring an additional 107,570 shares during the period. Louisiana State Employees Retirement System bought a new stake in Repligen during the fourth quarter valued at about $2,625,000. Finally, Atria Investments Inc purchased a new position in Repligen during the third quarter valued at approximately $1,046,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.